Is olanzapine (Zyprexa) indicated for treatment of nausea and vomiting?

Olanzapine (Zyprexa) for Nausea and Vomiting

Olanzapine is NOT FDA-approved for nausea and vomiting, but it is strongly recommended by major oncology guidelines as an effective antiemetic for chemotherapy-induced nausea/vomiting (CINV), breakthrough nausea/vomiting, and palliative care settings. 1

FDA-Approved Indications vs. Clinical Use

The FDA has approved olanzapine exclusively for psychiatric conditions: schizophrenia, bipolar disorder, and acute agitation 1. However, this represents an off-label but guideline-supported use for antiemetic purposes.

Guideline-Supported Antiemetic Uses

Chemotherapy-Induced Nausea and Vomiting (CINV)

For highly emetogenic chemotherapy (HEC):

• NCCN 2017 guidelines recommend olanzapine as Category 1 evidence in combination with palonosetron and dexamethasone on day 1 2
• Can also be used as a 4-drug regimen: olanzapine + NK1 antagonist + palonosetron + dexamethasone 2
• ASCO 2017 guidelines give this a moderate strength recommendation with intermediate quality evidence 3

Dosing for CINV prevention:

• Standard dose: 5-10 mg orally daily 2
• Recent evidence suggests 5 mg may be as effective as 10 mg with potentially fewer side effects 4, 5

Breakthrough Nausea and Vomiting

Olanzapine is the preferred first-line agent for breakthrough CINV in patients who did not receive it prophylactically:

• NCCN lists it as Category 1 evidence at 5-10 mg PO daily 2
• ASCO 2017 recommends adding olanzapine for breakthrough symptoms with moderate strength recommendation 3
• One trial showed olanzapine was superior to metoclopramide: 70% vs 31% achieved no emesis (P<0.01) 3

Palliative Care Setting

For non-chemotherapy-related nausea and vomiting in palliative patients:

• NCCN Palliative Care guidelines recommend olanzapine as a dopamine receptor antagonist option 6
• Useful for persistent nausea when first-line agents fail 6

Postoperative Setting

WSES-GAIS-SIAARTI-AAST 2022 guidelines recommend dopaminergic pathway medications (including olanzapine alternatives like haloperidol) for postoperative nausea, but olanzapine is not specifically highlighted in this context 7

Clinical Efficacy Evidence

The evidence strongly supports olanzapine's antiemetic efficacy:

• Meta-analysis shows olanzapine doubles the likelihood of no nausea/vomiting during chemotherapy from 25% to 50% (RR 1.98,95% CI 1.59-2.47) 5
• Number needed to treat (NNTB) = 5 5
• Particularly effective for delayed nausea and vomiting (24-120 hours post-chemotherapy) 8, 4, 5

Safety Profile

Common side effects:

• Somnolence and fatigue are the most significant concerns (RR 2.33,95% CI 1.30-4.18) 5
• Increased appetite and weight gain 6
• Risk of hyperglycemia and diabetes (FDA boxed warning for elderly with dementia) 1

Serious adverse events:

• Low incidence overall; uncertainty about increased risk (RR 2.46,95% CI 0.48-12.55) 5
• Grade ≥3 events are rare 8, 4

Critical caveat: Olanzapine carries an FDA boxed warning for increased mortality in elderly patients with dementia-related psychosis 1. Use caution in this population.

Practical Dosing Algorithm

For CINV prevention:

1. Start with 5 mg orally daily on days 1-4 of chemotherapy
2. Consider 10 mg if 5 mg inadequate (though evidence suggests similar efficacy) 4, 5

For breakthrough nausea/vomiting:

1. If patient did NOT receive olanzapine prophylactically: add 5-10 mg PO daily 2, 3
2. If already on olanzapine: switch to different drug class (NK1 antagonist, benzodiazepine, or cannabinoid) 3

For palliative care:

• Use as part of multimodal approach when first-line dopamine antagonists (metoclopramide, prochlorperazine) fail 6

Key Clinical Pearls

• Oral formulation only in available evidence—no data supporting IV/IM use for nausea 5
• More effective for delayed than acute nausea/vomiting 5
• Monitor for sedation, especially in elderly or when combined with other CNS depressants 1
• Check blood glucose in diabetic patients or those at risk 1
• Consider lower 5 mg dose to minimize somnolence while maintaining efficacy 4

Bottom Line

While olanzapine lacks FDA approval for nausea and vomiting, it has strong guideline support (NCCN Category 1, ASCO moderate recommendation) as an effective antiemetic, particularly for chemotherapy-induced and breakthrough nausea/vomiting. The 5 mg dose appears to optimize the benefit-risk ratio. Use is off-label but evidence-based and widely accepted in oncology practice.